Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
NCT02131025: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Active, not recruiting
3
428
US, Canada
ABC/DTG/3TC FDC, Ongoing cART regimen
ViiV Healthcare, PPD, GlaxoSmithKline
Infection, Human Immunodeficiency Virus
04/15
10/15
FLAIR, NCT02938520 / 2016-001646-25: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Active, not recruiting
3
631
Europe, Canada, Japan, US, RoW
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline
HIV Infections
08/18
12/26
2018-004885-32: THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR (D/L/A) TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) IN PATIENTS WITH SUPPRESSED VIRAL LOAD ON NEUROPSYCHIATRIC SIDE EFFECTS AND NEUROCOGNITIVE FUNCTION L’IMPATTO DEL PASSAGGIO DA DOLUTEGRAVIR/LAMIVUDINA/ABACAVIR (D/L/A) A BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE (B/F/TAF) NEI PAZIENTI IN TERAPIA ANTIRETROVIRALE CON HIVRNA SOPPRESSO SUGLI EVENTI AVVERSI NEUROPSICHIATRICI E SULLE FUNZIONI NEUROCOGNITIVE

Not yet recruiting
3
100
Europe
bictegravir/emtricitabina/tenofovir alafenamide, TRIUMEQ, [GS-9883-01], [dolutegravir/abacavir/lamivudina], Tablet, BIKTARVY, TRIUMEQ
AZIENDA OSPEDALIERA UNIVERSITARIA SENESE, Gilead Sciences
HIV-1 infection Infezione da HIV-1, Human immunodeficiency virus type 1 (HIV-1) infection Infezione da virus dell'immunodeficienza umana acquisita 1 (HIV-1), Diseases [C] - Virus Diseases [C02]
 
 
2020-005069-15: LIGHTHOUSE 2

Not yet recruiting
3
390
Europe
Triumeq, Capsule, Triumeq
Stichting TRICALS Foundation, ALS Stichting Nederland., Fight MND, Ulla-Carin Lindquist Foundation, Luzon Foundation, Research Motor Neurone
Amyotrophic Lateral Sclerosis (ALS), ALS/ Motor Neuron Disease (MND), Diseases [C] - Nervous System Diseases [C10]
 
 
2022-001437-36: ITACO study and the Analytical Antiretroviral Treatment Interruption study (ITACO-ATI) Studio ITACO e studio sull'interruzione del Trattamento Antiretrovirale (ITACO-ATI)

Not yet recruiting
3
61
Europe
ODEFSEY, REZOLSTA, BIKTARVY, Triumeq, Edurant, Tivicay, Descovy, Symtuza, Dovato, Epivir, [na], Film-coated tablet, ODEFSEY - 200 MG/25 MG/25 MG- COMPRESSA RIVESTITA- USO ORALE- FLACONE (HDPE) 30 COMPRESSE, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, Biktarvy, TRIUMEQ - 50MG/600MG/300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE HDPE - 1 FLACONE 30 COMPRESSE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, DESCOVY - 200 MG/10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, Symtuza, DOVATO - 50 MG / 300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EPIVIR - 300 MG 1 FLACONE 30 COMPRESSE RIVESTITE CON FILM USO ORALE
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, NIH (Johns Hopkins University)
perinatally HIV infection Infezione da HIV perinatale, perinatally HIV infection Infezione da HIV perinatale, Diseases [C] - Immune System Diseases [C20]
 
 
2020-001426-57: A study to compare whether giving two rather than three anti-HIV medicines daily to children and young people, aged between 2 and 15 years is assafe and effective in controlling their HIV infection Ensayo para comparar si la administración de dos en vez de tres fármacos anti-VIH diariamente en niños y pacientes jóvenes entre 2 y 15 años es tan segura y efectiva en el control de su infección por VIH.

Not yet recruiting
3
370
Europe
DTG/3TC DT, Dovato, Tivicay PD, Tivicay, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy, Dolutegravir, Dispersible tablet, Film-coated tablet, Capsule, hard, Dovato, TIVICAY PD, TIVICAY, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy
Fondazione Penta Onlus, ViiV Healthcare UK Limited
HIV Infection Infección por VIH, HIV Infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
NCT03016533: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Active, not recruiting
3
101
US, RoW
Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets
ViiV Healthcare
HIV Infections
11/24
11/24
Lighthouse III, NCT06658977: RolloverTreatment with Triumeq for People with ALS Following the Lighthouse II Trial

Not yet recruiting
3
70
RoW
Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
Macquarie University, Australia
Amyotrophic Lateral Sclerosis, ALS
12/26
12/26
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis

Active, not recruiting
3
390
Europe, RoW
Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo
Macquarie University, Australia, King's College London, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
08/26
08/26

Download Options